Agile: The new active ingredient in pharma development

In March 2019, two leaders of Roche’s agile transformation in product development—Frank Duff, senior vice president, and Malte Schutz, vice president—met with McKinsey’s Aliza Apple and Steven Aronowitz to discuss the origins of the work, its progress, and its potential. Frank Duff: If there is a ma...

Full description

Saved in:
Bibliographic Details
Published inMcKinsey Insights
Main Authors Apple, Aliza, Aronowitz, Steven
Format Magazine Article
LanguageEnglish
Published New York McKinsey & Company, Inc 07.06.2019
Subjects
Committees
Empowerment
Patients
Product development
Regulated industries
Teams
Online AccessGet full text

Cover

More Information
Summary:In March 2019, two leaders of Roche’s agile transformation in product development—Frank Duff, senior vice president, and Malte Schutz, vice president—met with McKinsey’s Aliza Apple and Steven Aronowitz to discuss the origins of the work, its progress, and its potential. Frank Duff: If there is a macro, it’s that many of the mind-set and behavioral shifts associated with agile are readily transferable to pharma. For the committee members, their roles have changed from waiting until a review meeting hits their calendars to becoming providers of advice and guidance when approached. McKinsey: If we could press you a bit on that: critics routinely say that agile is not possible in a highly regulated industry, like oil and gas, banking, insurance, or, indeed, pharmaceuticals.
Bibliography:content type line 24
ObjectType-Feature-1
SourceType-Magazines-1